Home World News Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive... World News Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer By Ogkologos - August 17, 2026 156 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PSMAddition study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Woman Dances Through Chemo Sessions, Emphasizes Importances of Being ‘Joyful’ March 4, 2021 Learning to Live With Cancer: A Survivor’s Story November 30, 2023 Targeted drug recommended to treat some advanced lung cancer patients November 25, 2021 Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab November 15, 2023 Load more HOT NEWS Cancer Survivor with Strong Family History Was Denied Regular Screening Because... Evaluating Targeted Therapy for People With Advanced Gastric or Gastroesophageal Junction... Do Birth Control Pills Impact My Cancer Risk? Emma Stone Motivated to Help Others After Her Mother Was Diagnosed...
